Previously viewed as a ‘nice to have’ for the pharma industry, virtual trials were already moving from a theoretical to a practical proposition before COVID-19 accelerated their transition.
In this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss the role that disease rarity plays in reimbursement decisions among payer
It has been five years since the first biosimilar launched in the United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients
The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, acc
